Silence Therapeutics plc (SLN) Institutional Ownership

Ownership Summary

Silence Therapeutics plc (NASDAQ:SLN) has 56 institutional investors that have filed 13F reports for the period ending March 2026.

• Collectively, these holders controlled 14.1% of Silence Therapeutics's outstanding shares in March 2026, up from 13.1% in December 2025.
• They increased total shares held in Silence Therapeutics by 17.52% from the prior quarter, while the number of investors in SLN decreased 8.2% year over year.
• During the quarter, 29 of these 56 funds increased positions in SLN, 13 reduced exposure, and 14 held steady.
• Institutional investors collectively held 19.91Mn shares in Silence Therapeutics as of March 2026, up by 2.97Mn shares quarter on quarter, and down 4.89Mn shares year over year.
• TCG Crossover Management, LLC leads ownership in SLN with 3.03Mn shares as of March 31, 2026, equal to 2.14% of outstanding shares.
• The most significant purchases of SLN for the quarter ending March 2026 came from CITADEL ADVISORS LLC (990.75K), Nantahala Capital Management, LLC (604.3K), MILLENNIUM MANAGEMENT LLC (414.6K), Jones Hill Capital LP (301.6K), Tetragon Partners GP Ltd (264.79K).
• The largest sales of SLN for the quarter ending March 2026 came from Morgan Stanley (259.14K), HSBC HOLDINGS PLC (222.83K), Seven Fleet Capital Management LP (138.44K), Ishara Investments LP (99.5K), M28 Capital Management LP (83.9K).
• Business Quant data shows the 10 biggest positions in Silence Therapeutics as of March 2026 are held by TCG Crossover Management, LLC (3.03Mn), Siren, L.L.C. (2.91Mn), Redmile Group, LLC (2.16Mn), Nantahala Capital Management, LLC (2.15Mn), CITADEL ADVISORS LLC (1.23Mn), MILLENNIUM MANAGEMENT LLC (1.07Mn), GREAT POINT PARTNERS LLC (1.02Mn), Nextech Invest, Ltd. (952.4K), Ikarian Capital, LLC (865.78K), Tetragon Partners GP Ltd (630.16K).